The efficacy of half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy_Chinese Journal of Ocular Fundus Diseases

Authors：

LuHuiqin , WangErqian ,  ChenYouxin

Department of Ophthalmology, Peking Union Medical College Hospital, Beijing 100730, China;

Corresponding author：

ChenYouxin, Email: chenyouxinpumch@163.com

Keywords：

Central serous chorioretinopathy/therapy; Photochemotherapy; Treatment outcome

DOI：

10.3760/cma.j.issn.1005-1015.2015.03.004

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To evaluate the efficacy and safety of half-dose verteporfin photodynamic therapy (PDT) for chronic central serous chorioretinopathy (CSC). Methods 35 eyes (35 patients) with chronic (or recurrent) CSC treated with half-dose verteporfin PDT. Best-corrected visual acuity(BCVA), central macular thickness (CMT) were measured before and after treatment (1, 3 and 6 months). The mean BCVA was 0.28±0.22, mean CMT was(384.5±85.0)μm. The situation of subretinal fluids (SRF) absorption was observed. Results In 35 eyes, SRF of 29 eyes (82.9%) completely absorbed and 6 eyes (17.1%) not completely absorbed after one month of treatment. SRF of all eyes (100.0%) completely absorbed after three months of treatment. After 6 months of treatment, SRF of 3 eyes (8.6%) were recurrence, which might be completely absorbed when a half-dose maintenance therapy PDT was used again. The mean BCVA significantly improved to 0.14±0.13 at 1 months, 0.05±0.11 at 3 months and 0.05±0.12 at 6 months after PDT (t=5.410, 7.830, 7.758; P < 0.05). The mean CMT decreased to (224.3±61.4) μm at 1 months, (199.6±32.7) μm at 3 months and (205.3±39.6) μm at 6 months after PDT (t=11.856, 11.781, 11.900; P < 0.05). The mean CMT of controlled 32 eyes after treatment was (198.5±33.9) μm, much lower than the fellow eyes(232.3±17.5) μm (t=-3.988, P < 0.05). Conclusions Half-dose verteporfin PDT was safe and effective in treating chronic CSC, but may cause thinning of CMT.

Citation： LuHuiqin, WangErqian, ChenYouxin. The efficacy of half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy. Chinese Journal of Ocular Fundus Diseases, 2015, 31(3): 226-229. doi: 10.3760/cma.j.issn.1005-1015.2015.03.004 Copy

1.	Quin G, Liew G, Ho IV, et al. Diagnosis and interventions for central serous chorioretinopathy:review and update[J]. Clin Experiment Ophthalmol, 2013, 41(2):187-200.
2.	Liegl R, Ulbig MW.Central serous chorioretinopathy[J]. Ophthalmologica, 2014, 232(2):65-76.
3.	Gass JD. Pathogenesis of disciform detachment of neuroepitheliumⅡ:idiopathic central serous choroidopathy[J]. Am J Ophthalmol, 1967, 63(3):587-615.
4.	Mazzolani F. Pilot study of oral administration of a curcumin-phospholipid formulation for treatment of central serous chorioretinopathy[J]. Clin Ophthalmol, 2012, 6:801-806.
5.	Chan WM, Lam DS, Lai TY, et al. Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin:a novel treatment at the primary disease level[J]. Br J Ophthalmol, 2003, 87(12):1453-1458.
6.	Colucciello M. Choroidal neovascularization complication photodynamic therapy for central serous retinopathy[J]. Retina, 2006, 26(2):239-242.
7.	Lai TY, Chan WM, Li H, et al. Safety enhanced photodynamic therapy with half dose verteporfin for chronic central serous chorioretinopathy:a short term pilot study[J]. Br J Ophthalmol, 2006, 90(7):869-874.
8.	Reibaldi M, Cardascia N, Longo A, et al. Standard-fluence versus low-fluence photodynamic therapy in chronic central serous chorioretinopathy:a nonrandomized clinical trial[J]. Am J Ophthalmol, 2010, 149(2):307-315.
9.	Shin JY, Woo SJ, Yu HG, et al. Comparision of efficacy and safety between half-fluence and full-fluence photodynamic therapy for chronic central serous chorioretinopathy[J]. Retina, 2011, 31(1):119-126.
10.	Alkin Z, Perente I, Ozkaya A, et al. Comparison of efficacy between low-fluence and half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy[J]. Clin Ophthalmol, 2014, 8:685-690.
11.	Nicolo M, Eandi CM, Alovisi C, et al. Half-fluence versus half-dose photodynamic therapy in chronic central serous chorioretinopathy[J]. Am J Ophthalmol, 2014, 157(5):1033-1037.
12.	李鹏程, 盛双燕, 彭冲, 等.半剂量光动力疗法治疗慢性中心性浆液性脉络膜视网膜病变[J].中华眼底病杂志, 2011, 27(4):327-330.
13.	Chan WM, Lai TY, Lai RY, et al. Safety enhanced photodynamic therapy for chronic central serous chorioretinopathy:one-year results of a prospective study[J]. Retina, 2008, 28(1):85-93.
14.	Lee JY, Chae JB, Yang SJ, et al. Intravitreal bevacizumab versus the conventional protocol of photodynamic therapy for treatment of chronic central serous chorioretinopathy[J]. Acta Ophthalmologica, 2011, 89(3):293-294.

1. Quin G, Liew G, Ho IV, et al. Diagnosis and interventions for central serous chorioretinopathy:review and update[J]. Clin Experiment Ophthalmol, 2013, 41(2):187-200.
2. Liegl R, Ulbig MW.Central serous chorioretinopathy[J]. Ophthalmologica, 2014, 232(2):65-76.
3. Gass JD. Pathogenesis of disciform detachment of neuroepitheliumⅡ:idiopathic central serous choroidopathy[J]. Am J Ophthalmol, 1967, 63(3):587-615.
4. Mazzolani F. Pilot study of oral administration of a curcumin-phospholipid formulation for treatment of central serous chorioretinopathy[J]. Clin Ophthalmol, 2012, 6:801-806.
5. Chan WM, Lam DS, Lai TY, et al. Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin:a novel treatment at the primary disease level[J]. Br J Ophthalmol, 2003, 87(12):1453-1458.
6. Colucciello M. Choroidal neovascularization complication photodynamic therapy for central serous retinopathy[J]. Retina, 2006, 26(2):239-242.
7. Lai TY, Chan WM, Li H, et al. Safety enhanced photodynamic therapy with half dose verteporfin for chronic central serous chorioretinopathy:a short term pilot study[J]. Br J Ophthalmol, 2006, 90(7):869-874.
8. Reibaldi M, Cardascia N, Longo A, et al. Standard-fluence versus low-fluence photodynamic therapy in chronic central serous chorioretinopathy:a nonrandomized clinical trial[J]. Am J Ophthalmol, 2010, 149(2):307-315.
9. Shin JY, Woo SJ, Yu HG, et al. Comparision of efficacy and safety between half-fluence and full-fluence photodynamic therapy for chronic central serous chorioretinopathy[J]. Retina, 2011, 31(1):119-126.
10. Alkin Z, Perente I, Ozkaya A, et al. Comparison of efficacy between low-fluence and half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy[J]. Clin Ophthalmol, 2014, 8:685-690.
11. Nicolo M, Eandi CM, Alovisi C, et al. Half-fluence versus half-dose photodynamic therapy in chronic central serous chorioretinopathy[J]. Am J Ophthalmol, 2014, 157(5):1033-1037.
12. 李鹏程, 盛双燕, 彭冲, 等.半剂量光动力疗法治疗慢性中心性浆液性脉络膜视网膜病变[J].中华眼底病杂志, 2011, 27(4):327-330.
13. Chan WM, Lai TY, Lai RY, et al. Safety enhanced photodynamic therapy for chronic central serous chorioretinopathy:one-year results of a prospective study[J]. Retina, 2008, 28(1):85-93.
14. Lee JY, Chae JB, Yang SJ, et al. Intravitreal bevacizumab versus the conventional protocol of photodynamic therapy for treatment of chronic central serous chorioretinopathy[J]. Acta Ophthalmologica, 2011, 89(3):293-294.

Chinese Journal of Ocular Fundus Diseases

The efficacy of half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content